Genomic epidemiology and resistance determinants of Pseudomonas aeruginosa in bronchiectasis across China: a multicentre study
Abstract
OBJECTIVES
To characterise the genomic epidemiology and resistance determinants of bronchiectasis-associated Pseudomonas aeruginosa in a multicentre cohort.
METHODS
We analysed 306 first non-duplicate P. aeruginosa isolates (2019-2021). Antimicrobial susceptibility was determined by broth microdilution and mucoid phenotype was recorded. Whole-genome sequencing was used for MLST, core-genome SNP phylogeny, resistance and virulence gene screening, and amino-acid variation in gyrA/gyrB/parC/parE, oprD, efflux regulators and mucoidy regulators (mucA, algU, mucB and mucD).
RESULTS
Mucoid isolates comprised 68.6% of the collection. 201 sequence types indicated a polyclonal population without geographic or phenotype-specific clustering. Resistance was highest to levofloxacin (41.5%) and ciprofloxacin (39.2%), and lowest to amikacin (0.3%). Multidrug-resistant isolates accounted for 16.3%. Species-associated determinants were near-universal (blaPAO, aph(3')-IIb, fosA, catB7 and blaOXA-50), whereas acquired genes were uncommon. Among fluoroquinolone-resistant isolates, 97.0% carried amino-acid changes in at least one quinolone target gene, with canonical QRDR hotspots alongside additional variants such as gyrA (S912_E913del) and gyrB (H148N). In imipenem-resistant isolates, oprD variation was detected in 98.1% (52/53). Mucoid isolates were enriched for mucA variation (88.6% vs 57.3%). Virulence profiling revealed a largely conserved repertoire characterised by alginate regulation,…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.